Congenital Alveolar Capillary Dysplasia (ACD/MPV)

Congenital alveolar capillary dysplasia, often shortened to ACD/MPV, is a rare lung problem that babies are born with. In ACD/MPV, the tiny air sacs in the lungs (alveoli) and the tiny blood vessels (capillaries) do not form the normal way during pregnancy. Because of this, oxygen cannot move well from air to blood. The blood vessels in the lungs are also abnormal and very tight, so the pressure in the lung arteries becomes very high (severe pulmonary hypertension). Most babies look well at birth but, within hours to a few days, they develop severe blue color (cyanosis) and very low oxygen levels that do not improve with usual treatments. The condition is usually caused by changes (mutations or deletions) in a gene called FOXF1 or its nearby control region on chromosome 16q24.1. The most certain way to diagnose ACD/MPV is by a lung tissue test (biopsy or autopsy) that shows too few capillaries, capillaries placed too far from the air sacs, and misaligned pulmonary veins running alongside the arteries. Sadly, ACD/MPV is almost always fatal in newborns unless a lung transplant is possible. PMC+3PMC+3PMC+3

Congenital alveolar capillary dysplasia (ACD) is a birth-defect of the lungs. In this condition, the tiny air sacs (the alveoli) and their tiny blood vessels (capillaries) do not form in the normal way before birth. Because of this abnormal development, inhaled oxygen cannot pass well from air spaces into the blood. The newborn (usually a full-term baby who looked healthy at delivery) develops severe breathing trouble in the first hours or days of life. Oxygen levels stay low even with strong support, and pulmonary hypertension (very high pressure in lung arteries) quickly appears and progresses. Without a confirmed diagnosis and special decisions about care, ACD is usually fatal in the newborn period. A small number of babies with “patchy” or atypical disease may present later and can sometimes live longer or be considered for lung transplant. PMC+3PMC+3MedlinePlus+3

Under the microscope, doctors see a classic picture: very few capillaries close to the alveolar lining, thick alveolar walls, over-grown muscle in small arteries, and pulmonary veins that run in the wrong place (the veins abnormally lie next to small arteries—this is called “misalignment”). These structural errors explain why oxygen cannot move into blood and why lung blood pressure rises. PMC

Other names

• Alveolar capillary dysplasia with misalignment of pulmonary veins (short forms: ACD/MPV or ACDMPV)

• Congenital alveolar capillary dysplasia

• Misaligned pulmonary veins syndrome
  All of these point to the same core disorder. PMC+1

Types

Because this is a rare disease, there is no single, universal “official list of types.” Clinicians often group ACD by how it looks, when it appears, and what genes are found:

1. Classic, early-onset ACD/MPV. Full-term baby becomes breathless within hours of birth, has severe, oxygen-resistant low oxygen levels, and develops pulmonary hypertension quickly. Histology shows the classic pattern in most lung tissue. PMC+1

2. Atypical or patchy ACD. Disease is not spread evenly through the lungs. Babies may present later (days to weeks or even months), sometimes during an intercurrent illness. These cases can live longer and, in selected centers, may be considered for lung transplantation. PMC

3. Genetically confirmed ACD (FOXF1-related). A disease-causing change is found in the FOXF1 gene or in its upstream enhancer region on chromosome 16q24.1. PubMed+2PubMed+2

4. Clinically/pathologically diagnosed ACD without a detected variant. The baby has the ACD pattern on biopsy or autopsy, but genetic testing does not find a change. This can happen because current tests may miss some regulatory or epigenetic changes. PMC

5. Syndromic ACD. ACD occurs with other birth defects (e.g., heart defects, intestinal malrotation, genitourinary anomalies). These associations are common and can be a clue. PMC

Causes

Key point: ACD is a developmental lung disorder. The strongest, best-proven cause is reduced activity (“haploinsufficiency”) of the FOXF1 gene or disruption of its long-range enhancer. Many changes below are different ways that the FOXF1 “instruction set” can be lost or silenced. Where evidence is limited, I say so.

1. De novo loss-of-function mutation in FOXF1. A new (not inherited) damaging change—nonsense, frameshift, splice—leads to too little FOXF1 protein during lung development. This is one of the most frequent findings. PubMed+1

2. Microdeletion of 16q24.1 including FOXF1. A small missing DNA segment on chromosome 16 that removes the gene itself. PubMed

3. Deletion in the distant enhancer upstream of FOXF1. The gene remains intact, but a far-away “on-switch” is deleted, so expression drops and ACD results. PubMed+1

4. Disruption of enhancer-linked long non-coding RNAs (e.g., LINC01081/LINC01082). These RNAs sit inside the enhancer region and help regulate FOXF1. Their loss can down-regulate the gene. PubMed+1

5. Genomic imprinting effects at 16q24.1. Evidence suggests parent-of-origin matters for the enhancer: deletions on one parental copy have stronger effects than on the other. The net result is reduced FOXF1 in fetal lung. PubMed+2MDPI+2

6. Maternal-allele mutations. Several reports highlight maternally transmitted or maternal-allele changes linked to ACD, consistent with imprinting behavior. UCL Discovery

7. Regulatory “position effect.” A balanced or unbalanced chromosomal rearrangement can move enhancer pieces far from FOXF1, lowering its expression. (Rare but documented.) PMC

8. Copy-number–neutral changes in enhancer topology. Altered chromatin looping around the 15-kb core enhancer may reduce access to the promoter (mechanistic model from epigenetic studies). BioMed Central

9. Parental gonadal mosaicism. A parent carries the mutation in some egg/sperm cells without symptoms, leading to recurrence in siblings. (Uncommon but possible in many genetic conditions.) PMC

10. Child mosaicism. If only some fetal cells carry the defect, disease can be patchy, producing later or milder presentation. (Supported by patchy pathology in atypical cases.) PMC

11. Large 16q24.1 deletions spanning FOXF1 plus neighbors. Bigger losses that include FOXF1 and nearby genes; FOXF1 loss drives the lung phenotype. PubMed

12. Point mutations that alter FOXF1 DNA-binding domain. Missense variants can change the forkhead domain so the protein cannot control its targets. BioMed Central

13. Splice-site mutations. Changes at intron–exon junctions can mis-splice FOXF1 RNA, leading to a non-functional protein. PubMed

14. Promoter mutations or methylation changes (epigenetic). Rare or suspected; could silence the gene without altering its coding sequence. (Mechanism supported by enhancer methylation work.) BioMed Central

15. Unknown genetic cause despite testing. Some babies have classic ACD on biopsy but current tests are negative; undiscovered regulatory elements or epigenetic changes likely exist. PMC

16. New, very small enhancer deletions below routine test resolution. Ultra-small deletions may be missed by standard arrays; specialized assays can detect them. BioMed Central

17. Complex structural variants near 16q24.1. Inversions or translocations that separate the enhancer–promoter contact without losing DNA. (Mechanistic possibility consistent with position-effect principles.) BioMed Central

18. Pathway-level disruption upstream of FOXF1. FOXF1 is regulated by developmental signals (e.g., SHH pathway), so severe upstream defects could theoretically depress FOXF1 output and mimic ACD. Evidence is limited, but proposed in reviews. PMC

19. Very rare familial cases. Same pathogenic FOXF1 change found in affected relatives confirms heritable forms do occur, though most cases are de novo. BioMed Central

20. Idiopathic developmental error. In some, no molecular cause is found; the label remains idiopathic ACD based on pathology and clinical course. PMC

Summary: The dominant, well-supported theme is FOXF1 insufficiency—by a mutation, a deletion, or a broken enhancer. Other items above are best understood as different routes to the same endpoint: too little FOXF1 during lung development. PubMed+2PubMed+2

Symptoms and signs

Symptoms usually start within hours to days after birth in full-term infants. In atypical/patchy cases, signs may appear later (weeks to months).

1. Fast breathing (tachypnea). The baby breathes very quickly to try to get more oxygen.

2. Blue color (cyanosis). Lips and skin look blue because blood oxygen is low.

3. Grunting. A soft “ugh” sound at the end of breaths is a newborn’s way to keep air in the lungs.

4. Chest retractions. The skin pulls in between the ribs and at the neck with each breath, showing hard work of breathing.

5. Poor response to oxygen. Even 100% oxygen helps only a little because the blood vessels and capillaries are abnormal. PMC

6. Pulmonary hypertension signs. High pressure in lung arteries makes the heart work harder; echo shows high right-sided pressures. PMC

7. Low blood pressure or circulatory instability. As oxygen stays low and PH worsens, blood pressure can fall.

8. Pre-ductal vs post-ductal saturation difference. The right hand (pre-ductal) may have higher oxygen than the feet, a clue to right-to-left shunting.

9. Acidosis (acidic blood). Poor oxygen delivery leads to lactic acid build-up; ABGs show low O₂ and low pH.

10. Poor feeding and lethargy. Babies may be sleepy and unable to feed because of low oxygen.

11. Cool extremities and poor perfusion. Blood flow is directed to vital organs; hands and feet may feel cool.

12. Hepatomegaly (big liver). Back-up from the right heart can enlarge the liver.

13. No improvement with surfactant or inhaled nitric oxide alone. Temporary changes may occur, but sustained recovery does not happen because the lung architecture is wrong. PMC

14. Later or episodic hypoxemia in atypical cases. Patchy disease can cause recurrent desaturations during infections or stress. PMC

15. Associated birth defects. Some babies also have heart, intestinal, or urinary tract anomalies, which can be a diagnostic clue. PMC

Diagnostic tests

Goal of testing: stabilize the baby, exclude more common causes of hypoxemia, look for clues of ACD, and—when safe and appropriate—confirm the diagnosis by genetics and/or lung pathology.

A) Physical exam and bedside observations

1. General newborn assessment. Check color, breathing rate, work of breathing, and alertness. The pattern “severe distress in a term baby that does not respond to oxygen” should raise suspicion. PMC

2. Pre- vs post-ductal oxygen saturation comparison. Right hand vs foot oximetry can show right-to-left shunting from pulmonary hypertension.

3. Cardiovascular exam. Tachycardia, a loud second heart sound (P2), signs of right-sided strain, and sometimes low blood pressure are common with severe PH.

4. Abdominal exam for hepatomegaly. A large, tender liver suggests right-sided heart stress.

5. Syndromic survey for associated anomalies. Look for murmurs, abdominal distension (malrotation), and genitourinary anomalies. These associated defects can point to ACD. PMC

B) Bedside “manual” or functional tests

6. Hyperoxia test (100% oxygen). In problems like simple lung collapse or pneumonia, 100% oxygen improves PaO₂ a lot. In ACD, improvement is small or absent because the capillary bed is abnormal. PMC

7. Gentle ventilation/PEEP trial. If compliance is near-normal and oxygenation still fails, think beyond surfactant deficiency. ACD lungs often look near-normal on mechanics but oxygenation is poor. PMC

8. Inhaled nitric oxide trial. Transient fall in PH may occur, but sustained improvement is unusual in ACD; a poor or short-lived response is a clue. PMC

9. Pre- and post-ductal gradient monitoring over time. Persistent or widening gradient under support suggests refractory PH, seen in ACD.

10. Trial of exogenous surfactant. Lack of meaningful response (vs neonatal RDS or MAS) nudges the differential toward ACD. PMC

C) Laboratory and pathological tests

11. Arterial blood gas (ABG). Shows refractory hypoxemia and acidosis despite high oxygen delivery.

12. Serum lactate and metabolic panel. High lactate reflects poor tissue oxygen delivery.

13. CBC, cultures, and inflammatory markers. Rule out sepsis and pneumonia, far more common causes of neonatal hypoxemia.

14. Genetic testing for FOXF1 sequence variants and copy-number changes. Use targeted FOXF1 testing or a panel that covers FOXF1 and its enhancer region (e.g., chromosomal microarray or CNV analysis). A positive result supports diagnosis without waiting for biopsy. Laboratory Investigation+1

15. Enhanced analysis of the distant enhancer (16q24.1). If sequencing is negative, consider specialized assays to look for small enhancer deletions or structural changes. BioMed Central

16. Lung histopathology (surgical biopsy or, if no other option, autopsy). This is the gold-standard confirmation: misaligned pulmonary veins, paucity of alveolar capillaries near the epithelium, thickened septa, and muscularized small arteries. Biopsy must be done with extreme caution, and only if results will change management. PMC+1

D) Electrodiagnostic and physiologic monitoring

17. Continuous pulse oximetry (SpO₂). Documents persistent low oxygen saturations and pre-/post-ductal differences.

18. Electrocardiogram (ECG). May show right-ventricular strain patterns when pulmonary hypertension is severe.

19. Capnography. End-tidal CO₂ can help assess ventilation–perfusion mismatch and ventilator effectiveness.

20. Near-infrared spectroscopy (NIRS) when available. Tracks regional tissue oxygenation; persistently low cerebral/somatic saturation alongside low SpO₂ supports the severity of the oxygen-delivery problem.

E) Imaging tests

• Chest X-ray. Often shows diffuse hazy lungs without focal consolidation; not specific.

• Lung ultrasound. Helps exclude pneumothorax and large effusions; findings are usually non-specific in ACD.

• Echocardiography. Key test: shows high pulmonary artery pressure, right-to-left shunting across the ductus arteriosus or foramen ovale, and excludes structural heart disease. PMC

• High-resolution chest CT (when stable/appropriate). May be near-normal or show subtle interstitial change; cannot rule in ACD, but can support planning. PMC

• Cardiac catheterization (rare in unstable neonates). Direct PH measurement; risks are high in these patients and it usually does not change the ACD diagnosis pathway.

Non-pharmacological treatments (therapies & others)

Important: These measures support the baby. They do not cure ACD/MPV. They aim to keep oxygen delivery as good as possible while the team confirms the diagnosis and discusses goals of care.

1. Warm delivery room and gentle transition – reduce stress and oxygen demand at birth. Mechanism: lower metabolic need.

2. Minimal handling and noise – prevent desaturation from stimulation. Mechanism: reduces spikes in pulmonary pressure.

3. Careful oxygen titration – give enough oxygen to prevent severe hypoxemia while avoiding excess. Mechanism: improves oxygen gradient.

4. Mechanical ventilation – supports breathing when the baby cannot breathe effectively. Mechanism: provides pressure and oxygen to the lungs.

5. High-frequency ventilation (HFOV/HFJV) – very small, rapid breaths to limit lung injury. Mechanism: improves oxygenation with lower tidal volumes.

6. Sedation/comfort measures – reduce agitation-induced pulmonary vasoconstriction. Mechanism: lowers catecholamines and oxygen demand.

7. Prone or optimized positioning – may improve ventilation-perfusion matching. Mechanism: better dorsal lung aeration.

8. Temperature control (normothermia) – avoids cold stress that worsens hypoxemia. Mechanism: lowers oxygen consumption.

9. Gentle fluid management – avoid fluid overload that worsens lung edema. Mechanism: better lung compliance and gas exchange.

10. Nutritional support (enteral or parenteral) – provides calories for healing and growth. Mechanism: maintains metabolic reserves.

11. Infection prevention bundle – sterile lines, hand hygiene, early sepsis treatment. Mechanism: prevents added lung injury.

12. Echocardiography-guided hemodynamic care – tailor ventilation and circulatory support. Mechanism: treats real-time physiology.

13. Prostaglandin-maintained ductal patency (with drug, see below) as a strategy – keeps the ductus open to offload the right ventricle while decisions proceed. Mechanism: controlled right-to-left shunt reduces RV afterload. NCBI

14. Early consultation with ECMO team – prepare for extracorporeal support if chosen. Mechanism: provides gas exchange outside the body. PMC

15. Palliative care integration – supports family understanding and comfort if prognosis is poor. Mechanism: symptom relief, decision support. PMC

16. Family-centered communication and consent process – shared decisions about invasive care or biopsy/transplant evaluation. Mechanism: ethical, informed care.

17. Genetics counseling – explain FOXF1 testing and future pregnancy planning. Mechanism: risk assessment and options. PMC

18. Breast-milk feeding (if stable) or expressed milk via tube – optimal infant nutrition and immune factors. Mechanism: supports growth and lowers infection risk.

19. Skin-to-skin when feasible and safe – improves bonding and may stabilize vitals in selected, stable moments. Mechanism: neuro-hormonal calming.

20. Transport to tertiary NICU with transplant experience – if lung transplant is being considered. Mechanism: access to advanced therapies and evaluation. ScienceDirect

---

Drug treatments

Safety note: Do not use internet dosing for newborns. All neonatal doses are weight-based and must be set by NICU specialists. The medicines below are used supportively; none can fix the basic lung development problem in ACD/MPV. Evidence shows poor or only transient response to standard pulmonary hypertension drugs, which is a diagnostic clue. ScienceDirect

1. Inhaled nitric oxide (iNO) — Pulmonary vasodilator. When: early in severe hypoxemia. Purpose: trial to lower lung pressure. Mechanism: raises cGMP in smooth muscle to relax arteries. Side effects: methemoglobinemia, rebound PH when stopped; often no sustained benefit in ACD/MPV. ScienceDirect

2. Prostaglandin E1 (alprostadil) — Ductus arteriosus dilator. When: to keep duct open as a bridge/strategy. Purpose: offload right ventricle via controlled shunt. Mechanism: relaxes ductus smooth muscle. Side effects: apnea, hypotension—requires ICU monitoring. NCBI

3. Sildenafil — PDE-5 inhibitor. When: adjunct trial if iNO response is poor. Purpose: pulmonary vasodilation. Mechanism: increases cGMP by blocking breakdown. Side effects: hypotension; variable benefit in ACD/MPV. PMC

4. Milrinone — PDE-3 inhibitor/inodilator. When: RV dysfunction with high afterload. Purpose: improve heart squeeze and reduce lung artery tone. Mechanism: ↑cAMP. Side effects: hypotension, arrhythmias. NCBI

5. Epoprostenol/treprostinil/iloprost — Prostacyclin analogs. When: specialist use for PH. Purpose: vasodilation, anti-platelet effect. Mechanism: ↑cAMP in smooth muscle. Side effects: bleeding risk, hypotension; limited efficacy in ACD/MPV. PMC

6. Bosentan — Endothelin-receptor antagonist. When: selected refractory PH. Purpose: block vasoconstrictor endothelin-1. Mechanism: ETA/ETB blockade. Side effects: liver toxicity; neonatal data limited. PMC

7. Vasopressors (norepinephrine/epinephrine) — Vasoactive support. When: hypotension/shock. Purpose: maintain systemic pressure and coronary perfusion. Mechanism: α/β-adrenergic effects. Side effects: arrhythmia, reduced organ flow if excessive.

8. Inotropes (dopamine/dobutamine) — Cardiac support. When: RV dysfunction/low output. Purpose: improve pump function. Mechanism: β-adrenergic/dopaminergic. Side effects: tachyarrhythmia.

9. Diuretics (furosemide) — Fluid control. When: fluid overload. Purpose: reduce lung edema and RV strain. Mechanism: loop diuresis. Side effects: electrolyte imbalance.

10. Surfactant — Alveolar surface tension reducer. When: if RDS-like picture or secondary deficiency suspected. Purpose: improve compliance. Mechanism: restores surface activity. Side effects: transient desaturation/bradycardia; benefit in ACD/MPV uncertain. PMC

11. Antibiotics (empiric, then targeted) — Anti-infective. When: while ruling out sepsis/pneumonia. Purpose: treat possible infection. Mechanism: bactericidal/bacteriostatic. Side effects: drug-specific.

12. Sedatives/analgesics (e.g., fentanyl, morphine) — Comfort and ventilator synchrony. When: on ventilator/HFOV. Purpose: reduce stress vasoconstriction. Mechanism: CNS effects. Side effects: respiratory depression, hypotension.

13. Neuromuscular blockers (e.g., vecuronium) — Paralysis for HFOV/ECMO. When: severe ventilator dyssynchrony. Purpose: oxygenation stability. Mechanism: blocks acetylcholine at neuromuscular junction. Side effects: weakness, prolonged recovery.

14. Alkalinization (limited/older practice) — Sodium bicarbonate to raise pH. Purpose: transient pulmonary vasodilation. Mechanism: pH-mediated vascular tone. Side effects: CO₂ load, paradoxical acidosis; not routine. BioMed Central

15. Magnesium sulfate — Smooth muscle relaxant. When: adjunct vasodilator in PH crises. Purpose: lower vascular tone. Mechanism: calcium antagonism. Side effects: hypotension, respiratory depression.

16. Hydrocortisone (hemodynamic support) — Steroid. When: catecholamine-resistant shock. Purpose: improve vascular responsiveness. Mechanism: genomic effects on adrenergic receptors. Side effects: hyperglycemia, infection risk.

17. Proton-pump inhibitor/H₂ blocker — GI protection. When: critical illness, stress ulcers risk. Purpose/Mechanism: reduce gastric acid. Side effects: altered microbiome.

18. Anticoagulation (on ECMO) — Heparin. When: if ECMO chosen. Purpose: prevent circuit clotting. Mechanism: antithrombin activation. Side effects: bleeding. PMC

19. Vitamins and micronutrients (parenteral) — Nutrition support. When: TPN. Purpose: growth and healing. Mechanism: co-factors for metabolism.

20. Diuretics/afterload adjustments guided by echo — Tailored support. Purpose: optimize RV performance and oxygen delivery. Mechanism: hemodynamic modulation. NCBI

---

Dietary / molecular supplements

These do not treat or cure ACD/MPV. They are part of safe newborn nutrition if the baby is stable enough. Dosing is individualized by the NICU team.

1. Human breast milk (direct or expressed) – best overall nutrition; antibodies help lower infection risk. Mechanism: immune and growth factors.

2. Parenteral amino acids – maintain protein balance when feeding isn’t possible. Mechanism: provide essential substrates.

3. Intravenous lipid emulsions (include omega-3s) – energy and cell-membrane building blocks. Mechanism: essential fatty acids for growth.

4. Multivitamins (A, D, E, K) – support lung/immune/bone health. Mechanism: co-factors and antioxidant roles.

5. Minerals (calcium/phosphate) – bone and cellular function.

6. Trace elements (zinc, selenium, copper) – enzyme function and immunity.

7. Carnitine (when indicated) – fatty-acid transport into mitochondria.

8. Electrolyte management (sodium, potassium, magnesium) – heart and muscle function.

9. Iron (when appropriate) – red blood cell production; timing individualized.

10. Probiotics (only if unit protocol allows) – gut microbiome support in selected preterm infants; not ACD-specific. Mechanism: colonization resistance.

---

Immunity booster / regenerative / stem-cell” drugs

There is no proven regenerative or stem-cell drug for ACD/MPV at this time. Items below are research concepts or supportive; they should not be used outside expert protocols.

1. Mesenchymal stem cell (MSC) therapy (investigational) – studied in other neonatal lung diseases; concept is paracrine repair signals; not established for ACD/MPV.

2. Endothelial progenitor strategies (experimental) – idea to rebuild capillaries; no clinical evidence in ACD/MPV.

3. Recombinant growth factors (e.g., VEGF pathways, experimental) – theoretical capillary growth; safety concerns in neonates.

4. Antioxidant strategies (e.g., vitamin A, E) – supportive only; not curative.

5. Omega-3 fatty acids (nutrition) – anti-inflammatory cell-membrane effects; supportive.

6. Gene-targeted therapy to FOXF1/enhancer (future concept) – research focus; no clinical product available. ATS Journals+1

---

Surgeries / procedures

1. Bilateral lung transplantation – only definitive option that can correct the underlying lung problem when feasible. Why: replaces abnormal lungs. Reality: extremely rare in newborns, but case series and reports show survival after infant transplant. ScienceDirect+1

2. ECMO (veno-arterial) cannulation – machine temporarily replaces lung (and sometimes heart) function while decisions are made or as a bridge to transplant. Why: rescue oxygenation. PMC

3. Surgical lung biopsy – small piece of lung for diagnosis when the team believes results will change management. Why: pathological confirmation. UPMC Pathology

4. Repair of associated anomalies (e.g., intestinal malrotation) when stabilized – treats syndromic problems but does not fix ACD/MPV. Why: overall health if survival pathway exists. PMC

5. Central line/arterial line placement (procedural) – secure access for intensive care, ECMO, and medications. Why: safe delivery of life support.

---

Preventions

We cannot “prevent” ACD/MPV formation during pregnancy with lifestyle changes. These steps focus on planning and early detection.

1. Genetic counseling after an affected child. PMC

2. Offer parental and fetal genetic testing for FOXF1 region when indicated. Laboratory Investigation

3. Discuss options for future pregnancies (e.g., targeted prenatal testing). PubMed

4. Detailed fetal ultrasound and fetal echocardiography in at-risk pregnancies. PubMed

5. Delivery at a tertiary center with NICU and ECMO capacity when risk is known. PMC

6. Avoid non-essential medications and toxins in pregnancy (general good practice).

7. Routine maternal health visits to optimize overall fetal growth.

8. Newborn screening by vigilant clinical observation when history suggests risk.

9. Early echocardiography if a newborn of an at-risk family has any hypoxemia. NCBI

10. Autopsy with consent after an unexplained neonatal death to confirm diagnosis and guide future counseling. UPMC Pathology

---

When to see doctors

• During pregnancy: if prior child had ACD/MPV or 16q24.1/FOXF1 changes, ask for genetics and targeted prenatal testing early. PubMed

• At birth / first days: immediate care if a baby is blue, breathing fast, or not improving on oxygen. Request urgent echocardiography and NICU admission. If iNO fails and pulmonary hypertension is severe, clinicians should consider ACD/MPV and contact a center with lung pathology and transplant expertise. ScienceDirect+1

---

What to eat and what to avoid

• For the baby: if safe, human breast milk is preferred (direct or tube). If the baby is too unstable, the team will use parenteral nutrition (amino acids, fats, vitamins, minerals). There are no foods or supplements that cure ACD/MPV.

• For the breastfeeding mother: eat a balanced diet rich in protein, fruits, vegetables, whole grains, and healthy fats (including omega-3s). Stay hydrated. Avoid alcohol, smoking, and non-prescribed drugs. Follow any medication advice from obstetric and neonatal teams.

• Avoid: do not use over-the-counter supplements for the baby without NICU orders. Do not delay medical care while trying home remedies.

---

Frequently asked questions (FAQs)

1. Is ACD/MPV the same as PPHN?
   No. PPHN is a circulation problem that often improves with iNO and supportive care. ACD/MPV is a lung development problem where capillaries and veins are abnormal, so standard PPHN treatments usually do not work well. NCBI+1

2. How is ACD/MPV confirmed?
   By lung pathology (biopsy or autopsy). Genetic tests for FOXF1 changes support the diagnosis but pathology is definitive. UPMC Pathology

3. Can an ultrasound in pregnancy see ACD/MPV?
   Not directly. Sometimes there are clues (associated anomalies), and genetic tests can detect 16q24.1/FOXF1 changes. PubMed

4. Why does nitric oxide not help much?
   Because the capillary network is sparse/misaligned, so even if arteries relax, oxygen still cannot move well into blood. ScienceDirect

5. Is there any cure without transplant?
   At present, no. Supportive care can buy time and comfort, but only lung transplantation replaces the abnormal lungs. ScienceDirect

6. Do all babies with ACD/MPV die quickly?
   Most do in the newborn period. Very rare “patchy/late” cases may live longer before decline. PMC

7. Can ECMO cure ACD/MPV?
   No. ECMO can temporarily take over oxygenation and may bridge to transplant or allow diagnosis, but it cannot fix the lungs. PMC

8. Is ACD/MPV inherited?
   Often changes are de novo (new in the child), but inherited cases exist. Genetic counseling is recommended. PMC

9. What else can look like ACD/MPV?
   Severe PPHN from meconium aspiration, sepsis, or congenital diaphragmatic hernia, and other rare interstitial lung diseases. BioMed Central

10. Can we try many pulmonary hypertension drugs “just in case”?
    Specialists may trial some, but lack of response is common and can help point to ACD/MPV. Risks and benefits must be weighed carefully. PMC+1

11. Will a biopsy make my baby worse?
    A biopsy carries risk in critically ill neonates and is considered only if results would change management (e.g., transplant pathway). UPMC Pathology

12. Are there research trials?
    Because the disease is very rare, trials are limited. Some centers study genetics and lung development pathways (e.g., FOXF1/STAT3). Ask your team about registries. ATS Journals

13. If we had one affected child, what about future pregnancies?
    Targeted prenatal testing and early planning at a tertiary center are appropriate. PubMed

14. Can diet or supplements cure ACD/MPV?
    No. Nutrition supports growth and recovery but does not correct the lung development problem.

15. Where can I read more?
    Authoritative summaries are available from peer-reviewed reviews and rare-disease resources. PMC+2PMC+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 14, 2025.